Outcomes of ovarian stimulation in the follicular and luteal phases of the menstrual cycle in cancer patients

Figures & data

Figure 1. Nosological entities of oncological diseases.

Table 1. Baseline characteristics of patients in both groups.

	Follicularphase (n = 68)	Lutealphase (n = 72)	p
Age, years	33.38 (3.73)	33.3 (5.47)	.255
BMI, kg/m^2	23.2 (2.2)	21.2 (1.6)	.185
AMH, ng/mL	1.5 (1.1–3.2)	1.8 (1.2–3.5)	.196

Table 2. Cycle characteristics in the follicular and luteal phase stimulation groups.

	Follicularphase (n = 68)	Lutealphase (n = 72)	p
Lengthofstimulation (days)	8 (7–10)	9 (6.5–11)	.477
Gonadotropindosage (IU)	2025 (1706–2288)	2400 (2013–2725)	.002

Table 3. Comparison of hormonal parameters between groups.

	Follicular phase (n = 68)	Luteal phase (n = 72)	p-value
Basal LH-1, IU/L	4.5	5.2	.608
	(2.6–7.3)	(1.9–8.3)
Day 6 LH-2, IU/L	2.4	2.8	.739
	(1.7–7.7)	(0.8–6.9)
Day of trigger admisitration LH-3, IU/L	1.8	1.4	.163
	(1.0–3.1)	(0.3–2.8)
Basal FSH,IU/L	9.1	7.3	.018
	(5.7–14.2)	(4.8–11.4)
Basal Estradiol-1, pmol / l	186	332	<.001
	(155–284)	(222–570)
Day 6 Estradiol-2, pmol / l	2765	1827	.010
	(1200–5336)	(936–2988)
Day of trigger admisitration Estradiol-3, pmol / l	7800	5544	.050
	(4139–12943)	(3047–8126)
Basal Progesterone −1, nmol / l	1.2	14.0	<.001
	(0.6–1.6)	(2.7–36.3)
Day 6 Progesterone −2, nmol / l	1.5	7.8	<.001
	(1.2–2.4)	(2.2–21.3)
Day of trigger admisitration Progesterone −3, nmol / l	3.1	3.7	.323
	(1.3–5.7)	(2.0–6.1)

Table 4. Parameters of oogenesis in patients depending on the phase of the menstrual cycle.

	Follicularphase (n = 68)	Lutealphase (n = 72)	p Value
Number of oocytes retrieved per patient (n)	7 (4–16)	10 (7–14)	.236
Total number of oocytes retrieved (n)	715	766
Number of metaphase II oocytes (n)	520 (72.8%)	557 (72.6%)	.521
MI	84 (11.7%)	68 (8.9%)	.042
GV	73 (10.2%)	100 (13.1%)	.052
Deg	38 (5.3%)	41 (5.4%)	.182